The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
α-Galactosylceramide Can Act As a Nasal Vaccine Adjuvant Inducing Protective Immune Responses against Viral Infection and Tumor
Open accessAbstract
α-Galactosylceramide (α-GalCer) is a ligand of invariant Vα14+ NKT cells and is presented by CD1d molecule on APC. NKT cells produce a large amount of Th1 and Th2 cytokines in response to α-GalCer-presented APC. In this study, we assessed whether α-GalCer could act as an effective nasal vaccine adjuvant for mucosal vaccine that would be capable of inducing systemic as well as mucosal immune responses. When α-GalCer was administered with OVA via the intranasal route to C57BL/6 and BALB/c mice, significant OVA-specific mucosal secretory IgA, systemic IgG, and CTL responses were induced with mixed Th1 and Th2 cytokine profiles seen in both strains of mice. Interestingly, as BALB/c mice were intranasally immunized with PR8 hemagglutinin Ag isolated from influenza virus A/PR/8/34 together with α-GalCer, significant protection was afforded against influenza viral infection. When α-GalCer was coimmunized with a replication-deficient live adenovirus to BALB/c mice, it significantly induced both humoral and cellular immune responses. In addition, intranasal administration of OVA with α-GalCer showed complete protection against EG7 tumor challenge in C57BL/6. The adjuvant effects induced by intranasal coadministration with α-GalCer were blocked in CD1d−/− mice, indicating that the immune responses were exclusively mediated by CD1d molecule on APC. Most interestingly, intranasally coadministered α-GalCer activated naive T cells and triggered them to differentiate into functional effector T cells when CFSE-labeled OT-1 cells were adoptively transferred into syngeneic mice. Overall, our results are the first to show that α-GalCer can act as a nasal vaccine adjuvant inducing protective immune responses against viral infections and tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Belshe, R. B., Mendelman, P. M., Treanor, J., King, J., Gruber, W. C., Piedra, P., Bernstein, D. I., Hayden, F. G., Kotloff, K., Zangwill, K., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805143382002 · Cited by 916
Cited by
Intranasal delivery: Physicochemical and therapeutic aspects
Costantino, H. R., Illum, L., Brandt, G., Johnson, P. H., & Quay, S. C. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.03.025 · Cited by 598
Harnessing invariant NKT cells in vaccination strategies
Cerundolo, V., Silk, J. D., Masri, S. H., & Salio, M. (2009) · Nature Reviews Immunology · doi:10.1038/nri2451 · Cited by 358
Influenza and the challenge for immunology
Doherty, P. C., Turner, S. J., Webby, R. G., & Thomas, P. G. (2006) · Nature Immunology · doi:10.1038/ni1343 · Cited by 356
Chapter 8 The Role of NKT Cells in Tumor Immunity
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)00408-9 · Cited by 316
Biology of CD1- and MR1-Restricted T Cells
Salio, M., Silk, J. D., Yvonne Jones, E., & Cerundolo, V. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120243 · Cited by 299
Metadata
- Authors
- Ko, S.-Y., Ko, H.-J., Chang, W.-S., Park, S.-H., Kweon, M.-N., & Kang, C.-Y.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-09-01
- Volume
- 175
- Issue
- 5
- Pages
- 3309-3317
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2134106722
- Cited by
- 182
- References
- 1
- FWCI
- 3.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: α-Galactosylceramide Can Act As a Nasal Vaccine Adjuvant Inducing Protective Immune Responses against Viral Infection and Tumor. https://app.cochat.ai/papers/10.4049/jimmunol.175.5.3309
- The paper
- Ko, S.-Y., Ko, H.-J., Chang, W.-S., Park, S.-H., Kweon, M.-N., & Kang, C.-Y. (2005). α-Galactosylceramide Can Act As a Nasal Vaccine Adjuvant Inducing Protective Immune Responses against Viral Infection and Tumor. The Journal of Immunology. https://doi.org/10.4049/jimmunol.175.5.3309
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.